Agent for treatment of dry eye characterized by combining p2y2 receptor agonist and hyaluronic acid or salt thereof, method for treating dry eye, and use of the p2y2 receptor agonist and hyaluronic acid or salt thereof
AssigneeSanten Pharmaceutical Co., Ltd.
InventorsYuko Shichijo, Atsuyoshi Dota, Takashi Nagano, Masatsugu Nakamura, Asuka Sakamoto
Life of this patent
Estimating the term…
Abstract
An agent for treatment of dry eye comprising a combination of a P2Y2 receptor agonist at a therapeutically effective concentration and hyaluronic acid or a salt thereof at a therapeutically effective concentration, which agent has a dosage form of an ophthalmic agent, can promote the secretion of tear remarkably and can improve corneal epithelial disorders remarkably, and is therefore expected to be a novel agent for treatment of dry eye.
Claims13
An agent for treatment of dry eye, characterized by comprising a combination of a P2Y2 receptor agonist at a therapeutically effective concentration and hyaluronic acid or a salt thereof at a therapeutically effective concentration, wherein the dosage form is an ophthalmic agent.
An ophthalmic solution for treating dry eye, characterized by comprising a combination of P1,P4-bis(5′-uridyl)tetraphosphate or a salt thereof at a concentration of 1 to 5% (w/v) and hyaluronic acid or a salt thereof at a concentration of 0.05 to 0.5% (w/v).
An ophthalmic solution for treating dry eye, characterized by comprising a combination of P1,P4-bis(5′-uridyl)tetraphosphate or a salt thereof at a concentration of 3% (w/v) and hyaluronic acid or a salt thereof at a concentration of 0.1 to 0.5% (w/v).
A method for treating dry eye, comprising administering a P2Y2 receptor agonist at a therapeutically effective concentration and hyaluronic acid or a salt thereof at a therapeutically effective concentration in combination to a patient in need thereof, wherein the dosage form is an ophthalmic agent.
A method for treating dry eye, comprising administering P1,P4-bis(5′-uridyl)tetraphosphate or a salt thereof at a concentration of 1 to 5% (w/v) and hyaluronic acid or a salt thereof at a concentration of 0.05 to 0.5% (w/v) in combination to a patient in need thereof, wherein the dosage form is an ophthalmic solution.
A method for treating dry eye, comprising administering P1,P4-bis(5′-uridyl)tetraphosphate or a salt thereof at a concentration of 3% (w/v) and hyaluronic acid or a salt thereof at a concentration of 0.1 to 0.5% (w/v) in combination to a patient, wherein the dosage form is an ophthalmic solution.
13-24. (canceled)
Dependencies are inferred from the claim text.